All In Biotech

NDA 021078 · Glaxosmithkline

Malarone Pediatric

Atovaquone, Proguanil Hydrochloride · Oral · Antimalarial; Antiprotozoal

Priority review

Last checked: Nov 20, 2026Latest source record: Jun 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Jul 14, 2000

Approved uses

3

Original approval plus efficacy supplements

Registered trials

57

5 Phase 3, 2 recruiting

FAERS reports

2,130

1,563 serious, 33 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 11, 2026.

Atovaquone and Proguanil Hydrochloride tablets are an antimalarial indicated for: • prophylaxis of Plasmodium falciparum (P. falciparum) malaria, including in areas where chloroquine resistance has been reported. ( 1.1 ) • treatment of acute, uncomplicated P. falciparum malaria. ( 1.2 ) 1.1 Prevention of Malaria Atovaquone and Proguanil Hydrochloride tablets are indicated for the prophylaxis of Plasmodium falciparum (P. falciparum) malaria, including in areas where chloroquine resistance has been reported. 1.2 Treatment of Malaria Atovaquone and Proguanil Hydrochloride tablets are indicated for the treatment of acute, uncomplicated P. falciparum malaria. Atovaquone and proguanil hydrochloride have been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and amodiaquine may have unacceptable failure rates, presumably due to drug resistance.

Mechanism: Atovaquone and Proguanil Hydrochloride tablets, a fixed-dose combination of atovaquone and proguanil hydrochloride, is an antimalarial agent [see Microbiology ( 12.4 )] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • MALARONE PEDIATRIC · ATOVAQUONE 62.5MG; PROGUANIL HYDROCHLORIDE 25MG · TABLET, ORAL · Prescription · TE AB
  • MALARONE · ATOVAQUONE 250MG; PROGUANIL HYDROCHLORIDE 100MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Atovaquone" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea193
  • diarrhoea170
  • vomiting153
  • pyrexia150
  • headache132
  • malaria123
  • drug ineffective122
  • dizziness112
  • fatigue108
  • malaise102
  • rash82
  • hallucination76

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004121
2005169
2006160
2007192
2008162
2009133
2010106
2011131
2012111
2013103
201488
201580
201689
201773
201883
201975
202037
202120
202249
202333
202446
202539
202630

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Malarone (Atovaquone/Proguanil HCl)

2024 spending

$3K

Beneficiaries

23

24 claims

Per beneficiary

$142

$5.96 per unit

View as table
YearSpending
2020$0
2021$0
2022$3,317
2023$3,409
2024$3,260

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 133 on PubMed

Sponsor: GSK · Also marketed as Malarone

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.